Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 14;2(3):100129.
doi: 10.1016/j.bneo.2025.100129. eCollection 2025 Aug.

Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy

Suravi Raychaudhuri  1   2 , Megan Othus  2 , Mary-Elizabeth M Percival  1   2 , Guillermo Garcia-Manero  3 , Frederick R Appelbaum  1   2 , Harry P Erba  4 , Jacob S Appelbaum  1   2
Affiliations

Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy

Suravi Raychaudhuri et al. Blood Neoplasia. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: M.O. reports consulting fees from Merck and BioSight; and data safety monitoring board fees from Celgene/Bristol Myers Squibb, Grifols, and GlycoMimetics. M.-E.M.P. reports research funding from AbbVie, Ascentage, Astex, BioSight, Bristol Myers Squibb, Cardiff Oncology, GlycoMimetics, Immunogen, Pfizer, Telios, and Vincerx. The remaining authors declare no competing financial interests.

References

    1. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377. - PubMed
    1. O’Connell NS, Zhao F, Lee J-W, et al. Importance of low- and moderate-grade adverse events in patients’ treatment experience and treatment discontinuation: an analysis of the E1912 trial. JCO. 2024;42(3):266–272. - PMC - PubMed
    1. Seymour JF, Byrd JC, Ghia P, et al. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023;142(8):687–699. - PMC - PubMed
    1. Gambacorti-Passerini C, Cortes JE, Lipton JH, et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol. 2014;89(10):947–953. - PMC - PubMed
    1. Garcia-Manero G, Podoltsev NA, Othus M, et al. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia. 2024;38(1):58–66. - PMC - PubMed

LinkOut - more resources